ONCIN — Oncoinvent ASA Share Price
Last trade - 00:00- NOK305.43m
- NOK200.69m
- NOK28.07m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.79 | ||
| Price to Tang. Book | 3.79 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 9.68 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -214.21% | ||
| Return on Equity | -228.94% | ||
| Operating Margin | -547.52% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | NOKm | 0.77 | 0.39 | 0.35 | 8.1 | 28.07 | 18.5 | 12 | 115.71% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Oncoinvent ASA, formerly Bergenbio ASA, is a Norway-based clinical-stage biopharmaceutical company focused on developing drugs for aggressive diseases including cancer and severe respiratory infections. The Company's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) which is a tyrosine kinase target that mediates aggressive disease. Under normal healthy physiological conditions, there is low expression of AXL. However, in aggressive diseases, such as cancer and severe respiratory infections, AXL signaling is upregulated in response to hypoxia, inflammation, cellular stress and drug treatment. The Company's flagship product is BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in Phase II clinical trials in cancer indications and COVID-19. The Company is based in Bergen, Norway with a subsidiary in Oxford, UK.
Directors
- Anders Tullgren CHM (61)
- Rune Skeie CFO (44)
- Endre Kjaerland OTH
- Julia Schoelermann OTH
- Dominic Smethurst OTH
- Victoria Wills OTH
- Sveinung Hole DRC
- Martin Olin DRC (52)
- Debra Barker NED (58)
- Grunde Eriksen NED
- Pamela Trail NED
- Stener Kvinnsland NID
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- January 31st, 2008
- Public Since
- April 7th, 2017
- No. of Employees
- 42
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Oslo Stock Exchange
- Shares in Issue
- 4,478,412
- Address
- Gullhaugveien 7, OSLO, 0484
- Web
- https://www.oncoinvent.com/
- Phone
- +47 22183305
- Auditors
- Ernst & Young AS
Latest News for ONCIN
Upcoming Events for ONCIN
Q3 2026 Oncoinvent ASA Earnings Release
Q4 2026 Oncoinvent ASA Earnings Release
Similar to ONCIN
Arctic Bioscience AS
Oslo Stock Exchange
Arcticzymes Technologies ASA
Oslo Stock Exchange
Navamedic ASA
Oslo Stock Exchange
Photocure ASA
Oslo Stock Exchange
Vistin Pharma ASA
Oslo Stock Exchange
FAQ
As of Today at 04:30 UTC, shares in Oncoinvent ASA are trading at NOK68.20. This share price information is delayed by 15 minutes.
Shares in Oncoinvent ASA last closed at NOK68.20 and the price had moved by -5.99% over the past 365 days. In terms of relative price strength the Oncoinvent ASA share price has underperformed the FTSE Global All Cap Index by -17.64% over the past year.
The overall consensus recommendation for Oncoinvent ASA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreOncoinvent ASA does not currently pay a dividend.
Oncoinvent ASA does not currently pay a dividend.
Oncoinvent ASA does not currently pay a dividend.
To buy shares in Oncoinvent ASA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of NOK68.20, shares in Oncoinvent ASA had a market capitalisation of NOK305.43m.
Here are the trading details for Oncoinvent ASA:
- Country of listing: Norway
- Exchange: OSL
- Ticker Symbol: ONCIN
Based on an overall assessment of its quality, value and momentum Oncoinvent ASA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Oncoinvent ASA is NOK112.50. That is 64.96% above the last closing price of NOK68.20.
Analysts covering Oncoinvent ASA currently have a consensus Earnings Per Share (EPS) forecast of -NOK33.52 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Oncoinvent ASA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +34.43%.
As of the last closing price of NOK68.20, shares in Oncoinvent ASA were trading +11.35% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Oncoinvent ASA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at NOK68.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Oncoinvent ASA's management team is headed by:
- Anders Tullgren - CHM
- Rune Skeie - CFO
- Endre Kjaerland - OTH
- Julia Schoelermann - OTH
- Dominic Smethurst - OTH
- Victoria Wills - OTH
- Sveinung Hole - DRC
- Martin Olin - DRC
- Debra Barker - NED
- Grunde Eriksen - NED
- Pamela Trail - NED
- Stener Kvinnsland - NID